Skip to Content

Durysta Approval History

FDA Approved: Yes (First approved March 3, 2020)
Brand name: Durysta
Generic name: bimatoprost
Dosage form: Implant
Company: Allergan plc
Treatment for: Glaucoma, Open Angle, Intraocular Hypertension

Durysta (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

Development History and FDA Approval Process for Durysta

DateArticle
Mar  5, 2020Approval FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide